VACCITECH PLC (VACC)

Company Profile

Vaccitech Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. The company is headquartered in Didcot, Oxfordshire and currently employs 107 full-time employees. The company went IPO on 2021-04-30. The firm is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmunity. The company uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The company has a pipeline of both clinical and preclinical-stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB); VTP-200 for the treatment of human papilloma virus infection (HPV); VTP-850 for the treatment of prostate cancer; VTP-600 for the treatment of non-small cell lung cancer (NSCLC); VTP-1000 for the treatment of celiac disease, and VTP-1100 for the treatment of HPV-associated cancers. Its prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles, and VTP-500 for the prevention of Middle East respiratory syndrome (MERS).

Company Info

VACCITECH PLC

Unit 6-10, Zeus Building, Rutherford Avenue, Harwell

Didcot OXFORDSHIRE OX4 4GE

P: 4401865818808.0

CEO: William Enright

Employees: 107

Website: https://www.vaccitech.co.uk/